# POSTER NUMBER Sa1040

### INTRODUCTION

- Adequate bowel cleansing in preparation for colonoscopy improves outcomes, including adenoma and polyp detection rates<sup>1</sup>
  - Furthermore, high-quality bowel cleansing is required for detection of sessile serrated polyps, which are more difficult to detect with lowerquality cleansing<sup>2</sup>
- 1 L NER1006 (Plenvu; Salix Pharmaceuticals) is indicated in the United States for cleansing of the colon in preparation for colonoscopy in adults and may be administered as рм/ам (2-day) or ам/ам (1 day [morning-only]) split dosing<sup>3</sup>
- A same-day morning-only regimen may offer patients a convenient and less disruptive alternative to 2-day split-dosing regimens<sup>4</sup>

### OBJECTIVE

 To compare colon cleansing efficacy of 1 L NER1006 (administered as an ам/ам [morning-only] split-dosing regimen) versus 2 L polyethylene glycol (PEG) plus ascorbate (administered as a рм/ам [2-day] split-dosing regimen)

### METHODS

- Post hoc analysis of a multicenter, randomized, phase 3 clinical trial (ClinicalTrials.gov identifier: NCT02273167)<sup>5</sup>
- Patients were randomly assigned (1:1) to receive NER1006 administered as a 1-day, AM/AM split-dosing regimen or 2 L PEG plus ascorbate (MoviPrep; Norgine) administered as a рм/ам (2-day) split-dosing regimen<sup>5</sup>
- Central readers, who were blinded to treatment assignment, evaluated bowel cleansing quality strictly using the Boston Bowel Preparation Scale (BBPS)<sup>5</sup>
- BBPS utilizes a 4-point scoring system to assess 3 colonic regions: right colon (including the cecum and ascending colon), transverse colon (including the hepatic and splenic flexures), and left colon (including the descending colon, sigmoid colon, and rectum)<sup>6</sup>
- The 4-point scoring system ranges from 0 ("unprepared colon segment" with mucosa not seen due to solid stool that cannot be cleared") to 3 ("entire mucosa of colon segment seen well with no residual staining, small fragments of stool, or opaque liquid")
- Each colon segment is individually scored and the results are summed (total score, 0 ["unprepared colon"] to 9 ["perfectly clean colon with no residual liquid"])
- Definitions of colon cleansing success:
- Adequate cleansing: BBPS score  $\geq 2$  in each of the 3 regions
- High-quality cleansing: BBPS score  $\geq 2$  in each region and overall BBPS score ≥7
- Treatment groups were compared using a two-sided t-test
- Time-adjusted multiple logistic regression analysis was conducted to assess potential predictors of adequate and high-quality colon cleansing success
- Variables included age, male sex, height, weight, body mass index, type of colonoscopy (screening, surveillance), adherence, time lapse (time between last dose of bowel preparation to start of colonoscopy), and use of NER1006 bowel preparation
- Adherence was defined as the study drug compliance rate according to patient diaries, regardless of the amount of additional fluids consumed, for a rating of  $0 = \langle 75\% \rangle$  of each dose of bowel preparation;  $1 = \ge 75\%$  of each dose of bowel preparation; or 2 = 100% of each dose of bowel preparation

# Same-Day Morning-Only Dosing of 1 L NER1006, a Polyethylene Glycol Bowel Preparation, Nearly Doubles the Chance of High-Quality Cleansing Versus Standard 2 L Polyethylene Glycol and Ascorbate

Michael Epstein, MD<sup>1</sup>; Jonathan Manning, MD<sup>2</sup>; Christopher Allen, MS<sup>3</sup>; Marco Antonio Alvarez-Gonzalez, MD<sup>4</sup>

<sup>1</sup>Investigative Clinical Research, Annapolis, MD, USA; <sup>2</sup>Borders General Hospital, NHS Borders, Berwickshire, UK; <sup>3</sup>Salix Pharmaceuticals, Bridgewater, NJ, USA; <sup>4</sup>Hospital del Mar, Digestive Diseases, Barcelona, Spain

#### RESULTS

 530 patients were included in the analysis (NER1006 [n=270]; 2 L PEG plus ascorbate [n=260]; Table)

#### Table. Demographic and Baseline Characteristics


Parameter	NER1006 ам/ам Split-Dosing Regimen (n=270)	2 L PEG Plus Ascorbate рм/ам Split-Dosing Regimen (n=260)				
Age ≤65 y, n (%)	210 (77.8)	214 (82.3)				
Male sex, n (%)	125 (46.3)	137 (52.7)				
Race, n (%)		057 ( <u>00</u> 0)				
White Black	267 (98.9) 3 (1.1)	257 (98.8) 1 (0.4)				
Other	0	2 (0.8)				
BMI, kg/m <sup>2</sup> , mean (SD)	26.9 (4.3)*	26.4 (4.1)†				
Reason for colonoscopy, n (%)						
Diagnostic	76 (28.1)	71 (27.3)				
Screening	137 (50.7)	129 (49.6)				
Surveillance	57 (21.1)	60 (23.1)				
Time lapse, h, mean (SD)‡	5.4 (1.7)§	5.4 (2.1)¶				

Data from Manning J, et al.<sup>7</sup>

\*n=268. †n=256. ‡Time between last dose of bowel preparation to start of colonoscopy. §n=266. ¶n=253. BMI = body mass index; PEG = polyethylene glycol; SD = standard deviation.

- The percentage of patients with adequate colon cleansing was similar between NER1006 and 2 L PEG plus ascorbate (Figure 1)
- The percentage of patients with high-quality colon cleansing was numerically greater with NER1006 versus 2 L PEG plus ascorbate, although the difference was not statistically significant (Figure 1)

#### Figure 1. Adequate and High-Quality Colon Cleansing Rates With 1 L NER1006 AM/AM (Morning-Only) or 2 L PEG Plus Ascorbate 2-Day рм/ам Split-Dosing Regimen



PEG = polyethylene glycol.

• Although no specific variables were significantly associated with the odds of achieving adequate colon cleansing (Figure 2A), the NER1006 ам/ам morningonly regimen was significantly associated with achieving high-quality colon cleansing (Figure 2B; unadjusted, P<0.001; with Bonferroni correction for 11 assessed variables, P=0.01)

A. Variable	Favors 2 L PEG Plus Ascorbate Favors NER1		B. Variable	Favors 2 L PEG Plus Ascorbate Favors NER1006	OR (95% CI)
Age,	y I	0.98 (0.96-1.01)	Age, y		1.01 (0.99-1.03)
Male se	X I I	0.99 (0.43-2.29)	Male sex		1.17 (0.68-2.01)
Height, cn	n H	1.09 (0.89-1.35)	Height, cm		0.95 (0.82-1.10)
Weight, k	g F	0.90 (0.73-1.12)	Weight, kg		1.05 (0.90-1.23)
BMI, kg/m		1.27 (0.68-2.31)	BMI, kg/m²		0.85 (0.55-1.33)
Screening colonoscop	y I I	0.98 (0.48-1.96)	Screening colonoscopy		0.73 (0.46-1.15)
Surveillance colonoscop	y I I	1.42 (0.59-3.57)	Surveillance colonoscopy		0.83 (0.47-1.44)
Diagnostic colonoscop	y	Reference*	Diagnostic colonoscopy		Reference*
Adherence (0/1/2)	)†	1.40 (0.94-2.04)	Adherence (0/1/2) <sup>†</sup>		1.24 (0.94-1.65)
Time lapse, l	h H	0.99 (0.85-1.16)	Time lapse, h		0.99 (0.88-1.10)
NER1006 us		1.26 (0.70-2.27)	NER1006 use		1.93 (1.31-2.86)
	0.1 1 Adequate Colon Cleansing	100	0	High-Quality Colon Cleansing	100

#### Figure 2. Analysis of Potential Variables Impacting (A) Adequate and (B) High-Quality Colon Cleansing Success

\*Diagnostic group was used as a reference in the multivariate regression mode.

<sup>†</sup>According to patient diary, and regardless of additional fluids consumed, 0 = adherence rate <75% of each dose of bowel preparation; 1 = adherence rate <75% of each dose of bowel preparation; 1 = adherence rate <75% of each dose of bowel preparation; 1 = adherence rate <75% of each dose of bowel preparation; and 2 = adherence rate of 100% of each dose of bowel preparation.

BMI = body mass index; CI = confidence interval; OR = odds ratio; PEG = polyethylene glycol.

## CONCLUSIONS

The 1 L NER1006 AM/AM (morning-only) split-dosing bowel preparation regimen was associated with improved high-quality colon cleansing compared with 2 L PEG plus ascorbate рм/ам (2-day) split-dosing regimen Findings suggest that NER1006 administered the morning of colonoscopy may offer a highly effective and convenient alternative to a traditional overnight split-dosing regimen of 2 L PEG plus ascorbate

REFERENCES: 1. Clark BT, et al. Gastroenterology. 2016;150(2):396-405. 2. Clark BT and Laine L. Clin Gastroenterol. 4010;14(8):1155-1162. 3. Plenvu. Package insert. Salix Pharmaceuticals; 2021. 4. Longcroft-Wheaton G and Bhandari P. J Clin Gastroenterol. 2012;46(1):57-61. 5. Bisschops R, et al; MORA Study Group. Endoscopy. 2019;51(1):60-72. 6. Lai EJ, et al. Gastrointest Endosc. 2009;69(3 Pt 2):620-625. 7. Manning J, et al. BMC Gastroenterol. 2022;22(1):35 ACKNOWLEDGMENTS: The trial and post hoc analyses were supported by Norgine BV. Technical editorial and medical writing assistance were provided under direction of the authors by Mary Beth Moncrief, PhD, and Sophie Bolick, PhD, Synchrony Medical Communications, LLC, West Chester, PA. Funding for this assistance was provided by Salix Pharmaceuticals.

**DISCLOSURES:** ME reports acting as a safety advisor for Nestle HealthScience, and being a speaker for Bristol Myers Squibb, Pfizer Inc, and Redhill Biopharma Ltd. JM reports receiving honoraria from Norgine Ltd for speaking and for investigator advisory board attendance. CA is an employee of Salix Pharmaceuticals. MAA-G reports receiving honoraria from Norgine Ltd for advisory board attendance and from Casen-Recordati for speaking and teaching. PLENVU is a registered trademark of the Norgine group of companies used under license.



Research funded by: